Objectives To compare the diagnostic performance of 18 F-FDG PET/MRI and 18 F-FDG
PET/CT for primary and locoregional lymph node staging in non-small cell lung cancer …

Therapeutic decisions in non–small cell lung cancer (NSCLC) patients depend on the tumor
stage. PET/CT with 18F-FDG is widely accepted as the diagnostic standard of care. The …

Objective To investigate whether differences in thoracic tumour staging between 18 F-FDG
PET/CT and PET/MR imaging lead to different therapeutic decisions in Non-Small Cell Lung …

Purpose To compare the accuracy of different MR sequences in simultaneous PET/MR
imaging for T staging in non-small-cell lung cancer in relation to histopathology. Methods …

PURPOSE: Accurate staging of mediastinal lymph nodes metastases is critical for
determining the application of stereotactic body radiation therapy (SBRT) for patients with …

Purpose This study aimed to explore the clinical staging performance of [68 Ga] Ga-DOTA-
FAPI-04 PET/CT compared with that of 2-[18F] FDG PET/CT in non-small cell lung cancer …

Background Integrated 18F-fluorodeoxyglucose positron emission tomography/computed
tomography (18F-FDG PET/CT) is widely performed in hilar and mediastinal lymph node …

Purpose The nucleoside analog 3′-deoxy-3′-18 F-fluorothymidine (FLT) has been
introduced for imaging cell proliferation with positron emission tomography (PET). We …

Purpose: The aim of this study was to evaluate the diagnostic capacity of F-18
fluorodeoxyglucose dual-time-point (DTP) positron emission tomography (PET)/computed …

BACKGROUND: The treatment of patients with nonsmall cell lung cancer (NSCLC) is
determined by the stage. We evaluated the accuracy of staging using integrated positron …